Article Text

PDF
Extended report
Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients
  1. Ryan Webb1,2,
  2. Jennifer A Kelly1,
  3. Emily C Somers3,
  4. Travis Hughes1,
  5. Kenneth M Kaufman1,4,5,
  6. Elena Sanchez1,
  7. Swapan K Nath1,
  8. Gail Bruner1,
  9. Marta E Alarcón-Riquelme1,6,
  10. Gary S Gilkeson7,
  11. Diane L Kamen7,
  12. Bruce C Richardson3,8,
  13. John B Harley9,10,
  14. Amr H Sawalha1,4,5
  1. 1Arthritis & Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
  2. 2College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
  3. 3Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA
  4. 4Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
  5. 5US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA
  6. 6Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
  7. 7Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina, USA
  8. 8US Department of Veterans Affairs Medical Center, Ann Arbor, Michigan, USA
  9. 9Rheumatology Division and Autoimmune Genomics Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio USA
  10. 10US Department of Veterans Affairs Medical Center, Cincinnati, Ohio, USA
  1. Correspondence to Dr Amr H Sawalha, Department of Medicine, University of Oklahoma Health Sciences Center, 825 N.E. 13th Street, MS#24, Oklahoma City, Oklahoma 73104, USA; amr-sawalha{at}omrf.ouhsc.edu

Abstract

Background Systemic lupus erythematosus (SLE) is a chronic, multiorgan, autoimmune disease that affects people of all ages and ethnicities.

Objectives To explore the relationship between age at disease onset and many of the diverse manifestations of SLE. Additionally, to determine the relationship between age of disease onset and genetic risk in patients with SLE.

Methods The relationship between the age at disease onset and SLE manifestations were explored in a multi-racial cohort of 1317 patients. Patients with SLE were genotyped across 19 confirmed genetic susceptibility loci for SLE. Logistic regression was used to determine the relationships between the number of risk alleles present and age of disease onset.

Results Childhood-onset SLE had higher odds of proteinuria, malar rash, anti-dsDNA antibody, haemolytic anaemia, arthritis and leucopenia (OR=3.03, 2.13, 2.08, 2.50, 1.89, 1.53, respectively; p values <0.0001, 0.0004, 0.0005, 0.0024, 0.0114, 0.045, respectively). In female subjects, the odds of having cellular casts were 2.18 times higher in childhood-onset than in adult-onset SLE (p=0.0027). With age of onset ≥50, the odds of having proteinuria, cellular casts, anti-nRNP antibody, anti-Sm antibody, anti-dsDNA antibody and seizures were reduced. However, late adult-onset patients with SLE have higher odds of developing photosensitivity than early adult-onset patients. Each SLE-susceptibility risk allele carried within the genome of patients with SLE increased the odds of having a childhood-onset disease in a race-specific manner: by an average of 48% in Gullah and 25% in African-Americans, but this was not significant in Hispanic and European-American lupus patients.

Conclusions The genetic contribution towards predicting early-onset disease in patients with SLE is quantified for the first time. A more severe SLE phenotype is found in patients with early-onset disease in a large multi-racial cohort, independent of gender, race and disease duration.

Statistics from Altmetric.com

Footnotes

  • Funding This work was supported by the NIH grant number R03AI076729 from the National Institute of Allergy and Infectious Diseases, and NIH grants numbers P20-RR015577, P20- RR020143, P30-AR053483, P01-AI083194, P01-AR049084, N01-AR62277, R37-AI024717, R01-AR042460, UL1-RR029882, P60-AR049459, UL1-RR024986, the Lupus Foundation of America, Merit Award from the US Department of Veterans Affairs, the University of Oklahoma Health Sciences Center, the Oklahoma City VA Medical Center and the Oklahoma Medical Research Foundation.

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the Oklahoma Medical Research Foundation and the University of Oklahoma Health Sciences Center.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.